Stroke Association response to review into the use of alteplase

Dr Dale Webb, Director of Research and Information at the Stroke Association, said: “The findings of the Medicines and Healthcare Products Regulatory Agency’s review into alteplase will be extremely welcome news for stroke patients and their families. Stroke is the second biggest killer in the world, and one of the few existing treatments which can limit the brain damage caused by stroke is thrombolysis, which involves the use of alteplase.

“There is clear evidence for improved recovery in eligible stroke patients treated with thrombolysis. However, this type of treatment is not suitable for everyone struck down by stroke. That’s why the Stroke Association is leading the way in funding research to help transform the way stroke is treated. It is crucial that we find alternative ways to help improve the recovery rates from this devastating condition.”